Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

With the growing prevalence of atopic dermatitis and the increasing demand for innovative treatment options, the market for skin barrier assessment devices is expected to see significant growth in ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching ... is especially promising in treatment of this disease. Having been in ...

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...

Types of dermatitis Dermatitis encompasses various types, each with unique characteristics. Atopic Dermatitis ... may increase the risk. Treatment Homeopathic treatments, derived from natural ...

The new app addresses a skin disorder – commonly known as eczema – that affects up to 14% of adults worldwide and causes relentless itching ... treatment for moderate-to-severe atopic ...

ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including atopic dermatitis (AD), vitiligo, inflammatory ...